Evidence map›Paper›PMID 35751411›Full record

ArticleThe Journal of international medical research2022

Pralsetinib treatment for multiple

Xiangming Cao, Xiongwei Liu, Simin Wang, Zhen Liu, Xin Ren, Debin Sun, Lichun Deng

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xiangming CaoDepartment of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China.
Xiongwei LiuDepartment of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China.
Simin WangDepartment of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China.
Zhen LiuDepartment of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China.
Xin RenDepartment of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China.
Debin SunInstitute of Biomedical Research, Genecast Biotechnology Co., Ltd, Wuxi, China.
Lichun DengDepartment of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China.ORCID https://orcid.org/0000-0003-0322-1303
Jiangyin People's Hospital · CNGenecast (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection (

Indexed as

AdenocarcinomaAdenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansMaleProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyridinesPyrimidinespralsetinibProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyridinesPyrimidinesRET protein, humanLung adenocarcinomametastasisnext-generation sequencingpralsetinibRET fusiontyrosine kinase inhibitor

Identifiers

PMID35751411
PMCPMC9240590
OpenAlexW4283524028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.